Cost effectiveness of medication adherence-enhancing interventions: A systematic review of trial-based economic evaluations

PharmacoEconomics

Volumn 31, Issue 12, 2013, Pages 1155-1168

  Oberjé, Edwin J M ^a   De Kinderen, Reina J A ^b   Evers, Silvia M A A ^b   Van Woerkum, Cees M J ^c   De Bruin, Marijn ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKLIST; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE COST; HEART FAILURE; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; MEDLINE; PRIORITY JOURNAL; PSYCINFO; QUALITY CONTROL; RELIABILITY; REVIEW; SAMPLE SIZE;

COST-BENEFIT ANALYSIS; DATABASES, BIBLIOGRAPHIC; HEALTH PROMOTION; HUMANS; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84890390908     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0108-8     Document Type: Review

References (47)

1. Sabaté E. Adherence to long-term therapies: evidence for action, vol. 7. Geneva: World Health Organization; 2003. p. 48-9.
2. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes. A meta-analysis. Med Care. 2002;40(9):794-811.
3. Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184(6):509-16.
4. Colom F, Vieta E, Tacchi M, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord. 2005;7(s5):24-31.
5. White TJ, Vanderplas A, Ory C, et al. Economic impact of patient adherence with antidepressant therapy within a managed care organization. Dis Manage Health Outcome. 2003;11(12):817-22.
6. Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol. 2004;4(3):191.
7. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
8. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-25.
9. Scalera A, Bayoumi AM, Oh P, et al. Clinical and economic implications of non-adherence to HAART in HIV infection. Dis Manage Health Outcome. 2002;10(2):85-91.
10. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115(8):632.
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
12. Mahoney JJ, Ansell BJ, Fleming FWK, et al. The unhidden cost of noncompliance. J Manage Care Pharm. 2008;14:S1-29.
13. Cutler DM, Everett W. Thinking outside the pillbox - medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553-5.
14. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
15. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA. 2002;288(22):2868-79.
16. Roebuck MC, Liberman JN, Gemmill-Toyama M, et al. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff. 2011;30(1):91-9.
17. Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother. 2005;39(3):508-15.
18. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. USA: Oxford University Press; 2005.
19. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
21. Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357-9.
22. Krol M, Brouwer W, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter? Pharmacoeconomics. 2006;24(4):401-14.
23. Grosse SD. Assessing cost-effectiveness in healthcare: history of the 50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-78.
24. Bolton MB, Tilley BC, Kuder J, et al. The cost and effectiveness of an education program for adults who have asthma. J Gen Intern Med. 1991;6(5):401-7.
25. Bosmans JE, Brook OH, van Hout HPJ, et al. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants. Pharmacoeconomics. 2007;25(1):25-37.
26. Brunenberg DEM, Wetzels GEC, Nelemans PJ, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics. 2007;25(3):239-51.
27. Elliott RA, Barber N, Clifford S, et al. The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. Pharm World Sci. 2008;30(1):17-23.
28. Freedberg KA, Hirschhorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;43:S113-8.
29. Healey A, Knapp M, Astin J, et al. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry. 1998;172(5):420-4.
30. Hederos CA, Janson S, Hedlin G. Group discussions with parents have long-term positive effects on the management of asthma with good cost-benefit. Acta Paediatr. 2005;94(5):602-8.
31. Keeler EB, Robalino DA, Frank JC, et al. Cost-effectiveness of outpatient geriatric assessment with an intervention to increase adherence. Med Care. 1999;37(12):1199-206.
32. Khdour MR, Agus AM, Kidney JC, et al. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharmacol. 2011;33(4):665-73.
33. Murray D, Stroupe KT, Wu J, et al. Pharmacist intervention to improve medication adherence in heart failure. Ann Intern Med. 2007;146:714-25.
34. Schroeder K, Fahey T, Hollinghurst S, et al. Nurse-led adherence support in hypertension: a randomized controlled trial. Fam Pract. 2005;22(2):144-51.
35. von Knorring L, Åkerblad AC, Bengtsson F, et al. Cost of depression: effect of adherence and treatment response. Eur Psychiat. 2006;21(6):349-54.
36. Von Korff M, Katon W, Bush T, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosom Med. 1998;60(2):143-9.
37. Windsor RA, Bailey WC, Richards JM Jr, et al. Evaluation of the efficacy and cost effectiveness of health education methods to increase medication adherence among adults with asthma. Am J Public Health. 1990;80(12):1519-21.
38. de Bruin M, Viechtbauer W, Hospers HJ, et al. Standard care quality determines treatment outcomes in control groups of HAART-adherence intervention studies: implications for the interpretation and comparison of intervention effects. Health Psychol. 2009;28(6):668.
39. de Bruin M, Viechtbauer W, Schaalma HP, et al. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: a meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240.
40. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62(9):2091-100.
41. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1995;3(2):95-104.
42. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-87.
43. Briggs A. Economic evaluation and clinical trials: size matters. The need for greater power in cost analyses poses an ethical dilemma. BMJ. 2000;321(7273):1362-3.
44. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19(23):3219-36.
45. Boutron I, Estellat C, Guittet L, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med. 2006;3(10):e425.
46. Albrecht L, Archibald M, Arseneau D, Scott SD. Development of a checklist to assess the quality of reporting of knowledge translation interventions using the Workgroup for Intervention Development and Evaluation Research (WIDER) recommendations. Implement Sci. 2013;8:52.
47. Freedland KE, Mohr DC, Davidson KW, et al. Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med. 2011;73(4):323-35.